Market Place
Sourcing Support
Valeant`s Biologic Siliq (brodalumab) Receives Approval in the U.S.
19 Jul 2023 //
FDA
Ortho Dermatologics to Present Data at 2022 Innovations Dermatology Conference
01 Nov 2022 //
ACCESSWIRE
Valeant Luxembourg `s Siliq (brodalumab) Receives Approval in the U.S.
15 Jun 2022 //
FDA
Ortho Dermatologics To Present New Data At The 2021 Fall Clinical Dermatology
19 Oct 2021 //
PRNEWSWIRE
LEO Pharma initiates head-to-head study to evaluate brodalumab
13 Jan 2021 //
PRESS RELEASE
LEO Pharma initiates head-to-head study to evaluate brodalumab vs. guselkumab
13 Jan 2021 //
BUSINESSWIRE
Ortho Dermatologics To Present New Analyses At The Virtual Fall
26 Oct 2020 //
PRNEWSWIRE
Leo Pharma to market AstraZeneca’s brodalumab outside Europe
16 Aug 2019 //
PMLIVE
AbbVie`s rising immunology star Skyrizi scores nod from England`s cost watchdog
16 Jul 2019 //
FIERCE PHARMA
New data show that LEO Pharma’s Kyntheum® (brodalumab) sustains PASI 100
24 Apr 2019 //
BUSINESSWIRE
Valeant`s Biological Brodalumab Receives Approval in US
10 Oct 2018 //
FDA
LEO Pharma’s Kyntheum® (brodalumab) Achieving Complete Skin Clearance
13 Sep 2018 //
BUSINESSWIRE
FDA rejects Duobrii, a Valeant `Significant Seven` drug
19 Jun 2018 //
FIERCE PHARMA
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.